Biohaven Ltd. 8K

Biohaven Ltd. filed a current report to announce Q2 2026 financial results and significant clinical pipeline progress, including initiation and advancement of multiple pivotal and early-stage trials across immunology, neurology, obesity, and oncology programs.

On August 10, 2026, Biohaven Ltd. reported its financial results for the quarter ended June 30, 2026 and provided a comprehensive business update highlighting clinical and pipeline progress, including initiation of a pivotal Phase 3 trial for BHV-1300 in Graves’ disease, plans to begin a pivotal Phase 3 trial for BHV-1400 in IgA nephropathy in the second half of 2026, continued advancement of opakalim (BHV-7000) in epilepsy with a pivotal Phase 2/3 readout expected in the second half of 2026, ongoing development of several oncology antibody-drug conjugates in collaboration with Regeneron, first-in-human dosing of BHV-8100, and continued enrollment in a pivotal Phase 2/3 Parkinson’s disease study with BHV-8000, while disclosing that the company held approximately $270.5 million in cash, cash equivalents, marketable securities and restricted cash and incurred a GAAP net loss of $137.3 million for the quarter.

Filing Facts

CIK

1935979

Ticker

BHVN

Form

8K

Source Type

fda

Accession

0001935979-26-000067

Alert Tier

6